Literature DB >> 21928691

Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview.

Kohzo Nagata1, Takuya Hattori.   

Abstract

The incidence of cardiovascular events in hypertensive patients is clearly related to a left ventricular mass during treatment, and a regression of left ventricular hypertrophy is associated with a better prognosis. This is the case even independently of changes in other risk factors, including blood pressure. Evidence indicates that lifestyle modifications such as dietary salt restriction and weight loss are effective means in preventing the development of hypertension and reducing blood pressure and left ventricular mass in hypertensive patients. Salt restriction may also reduce the long-term risk of cardiovascular events. It has been recognized that the primary targets of current antihypertensive drugs are the renin-angiotensin-aldosterone system, calcium homeostasis, the ionic transport mechanisms in the kidneys, and the sympathetic nervous system. Clinical as well as experimental studies have demonstrated the cardioprotective effects of antihypertensive drugs independently of their blood pressure lowering effects. Hypertension is often complicated by other disease states including diabetes, dyslipidemia, and ischemic heart disease. Some of the drugs used for the treatment of such complications are also shown to produce cardioprotective effects in addition to their original effects. We ought to better understand these pleiotropic effects for the most effective treatments of hypertension and its complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21928691      PMCID: PMC4831218     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  65 in total

1.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

Authors:  M Takemoto; K Node; H Nakagami; Y Liao; M Grimm; Y Takemoto; M Kitakaze; J K Liao
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.

Authors:  Hideo Izawa; Toyoaki Murohara; Kohzo Nagata; Satoshi Isobe; Hiroyuki Asano; Tetsuya Amano; Sahoko Ichihara; Tomoko Kato; Satoru Ohshima; Yosuke Murase; Shigeo Iino; Koji Obata; Akiko Noda; Kenji Okumura; Mitsuhiro Yokota
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

3.  Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats.

Authors:  Jinglan Xu; Kohzo Nagata; Koji Obata; Sahoko Ichihara; Hideo Izawa; Akiko Noda; Tetsuro Nagasaka; Mitsunori Iwase; Tomoki Naoe; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  Hypertension       Date:  2005-09-19       Impact factor: 10.190

4.  Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization.

Authors:  D J Patel; H J Purcell; K M Fox
Journal:  Eur Heart J       Date:  1999-01       Impact factor: 29.983

5.  Physical activity and coronary heart disease in men: The Harvard Alumni Health Study.

Authors:  H D Sesso; R S Paffenbarger; I M Lee
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

6.  Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats.

Authors:  N Kobayashi; Y Mori; S Nakano; Y Tsubokou; H Shirataki; H Matsuoka
Journal:  J Hypertens       Date:  2001-04       Impact factor: 4.844

7.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

8.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

Authors:  Mirja Tiikkainen; Anna-Maija Häkkinen; Elena Korsheninnikova; Tuulikki Nyman; Sari Mäkimattila; Hannele Yki-Järvinen
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

9.  Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.

Authors:  Takehiro Ogata; Takashi Miyauchi; Satoshi Sakai; Masakatsu Takanashi; Yoko Irukayama-Tomobe; Iwao Yamaguchi
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

10.  Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats.

Authors:  Takashi Yamada; Kohzo Nagata; Xian Wu Cheng; Koji Obata; Masako Saka; Masaaki Miyachi; Keiko Naruse; Takao Nishizawa; Akiko Noda; Hideo Izawa; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  Eur J Pharmacol       Date:  2009-06-06       Impact factor: 4.432

View more
  2 in total

1.  Expression profile of matricellular proteins in hypertrophied right ventricle of monocrotaline-induced pulmonary hypertensive rats.

Authors:  Keisuke Imoto; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  J Vet Med Sci       Date:  2017-05-11       Impact factor: 1.267

2.  N-Propargyl caffeate amide (PACA) prevents cardiac fibrosis in experimental myocardial infarction by promoting pro-resolving macrophage polarization.

Authors:  Yuanyuan Cheng; Dan Luo; Yingke Zhao; Jianhui Rong
Journal:  Aging (Albany NY)       Date:  2020-03-23       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.